Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH6516 in Advanced Solid Tumors
NCT06266923Phase 1Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SPH6516 in solid tumor (advanced stage), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Jan 2022; status: completed.
02
Drugs
SPH6516
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06266923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06266923.